The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015;17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.
Because physicians are the gatekeepers to end-of-life care services and their referral patterns vary, those patterns are worthy targets for intervention.